HTG Molecular Diagnostics Inc. [NASDAQ: HTGM] traded at a low on 08/17/20, posting a -1.30 loss after which it closed the day’ session at $0.45. The company report on August 14, 2020 that HTG Molecular Provides Update on Patent Infringement Claims Against BioSpyder.
HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today provided an update regarding its patent infringement claims against BioSpyder Technologies, Inc (BioSpyder). On August 13, 2020, BioSpyder filed a lawsuit seeking a declaration that it does not infringe HTG’s U.S. Patent No. 8,741,564 (the ’564 patent). In several previous communications between the companies, HTG had asserted its claims that BioSpyder’s TempO-Seq® gene expression tool infringes the ‘564 patent.
“We believe our patents are strong, and we intend to vigorously enforce them just as any other IP-centric company would do,” said John L. Lubniewski, President and CEO of HTG. “We had previously offered the possibility of arriving at a negotiated settlement that recognizes our patent rights, but BioSpyder was clearly not interested in that approach. We look forward to a fair and speedy resolution of our infringement claims.”.
The results of the trading session contributed to over 2397257 shares changing hands. Over the past one week, the price volatility of HTG Molecular Diagnostics Inc. stands at 12.20% while the volatility over the past one month is 10.61%.
The market cap for HTGM stock reached $36.62 million, with 65.76 million shares outstanding and 48.68 million shares in the current float. Compared to the average trading volume of 5.65M shares, HTGM reached a trading volume of 2397257 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about HTG Molecular Diagnostics Inc. [HTGM]?
Cantor Fitzgerald have made an estimate for HTG Molecular Diagnostics Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on May 11, 2020. The new note on the price target was released on March 26, 2020, representing the official price target for HTG Molecular Diagnostics Inc. stock. Previously, the target price had yet another raise from $4.50 to $6, while Rodman & Renshaw kept a Buy rating on HTGM stock.
The Average True Range (ATR) for HTG Molecular Diagnostics Inc. is set at 0.07, with the Price to Sales ratio for HTGM stock in the period of the last 12 months amounting to 2.54. The Price to Book ratio for the last quarter was 1.62, with the Price to Cash per share for the same quarter was set at 0.41.
How has HTGM stock performed recently?
HTG Molecular Diagnostics Inc. [HTGM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -29.06. With this latest performance, HTGM shares dropped by -27.71% in over the last four-week period, additionally sinking by -23.77% over the last 6 months – not to mention a drop of -54.60% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HTGM stock in for the last two-week period is set at 30.78, with the RSI for the last a single of trading hit 23.76, and the three-weeks RSI is set at 37.21 for HTG Molecular Diagnostics Inc. [HTGM]. The present Moving Average for the last 50 days of trading for this stock 0.6530, while it was recorded at 0.5268 for the last single week of trading, and 0.5774 for the last 200 days.
HTG Molecular Diagnostics Inc. [HTGM]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and HTG Molecular Diagnostics Inc. [HTGM] shares currently have an operating margin of -102.09 and a Gross Margin at +53.60. HTG Molecular Diagnostics Inc.’s Net Margin is presently recorded at -100.49.
Return on Total Capital for HTGM is now -49.79, given the latest momentum, and Return on Invested Capital for the company is -53.22. Return on Equity for this stock declined to -85.65, with Return on Assets sitting at -43.42. When it comes to the capital structure of this company, HTG Molecular Diagnostics Inc. [HTGM] has a Total Debt to Total Equity ratio set at 71.00. Additionally, HTGM Total Debt to Total Capital is recorded at 41.52, with Total Debt to Total Assets ending up at 37.72. Long-Term Debt to Equity for the company is recorded at 50.39, with the Long-Term Debt to Total Capital now at 29.47.
Reflecting on the efficiency of the workforce at the company, HTG Molecular Diagnostics Inc. [HTGM] managed to generate an average of -$172,301 per employee. Receivables Turnover for the company is 4.70 with a Total Asset Turnover recorded at a value of 0.43.HTG Molecular Diagnostics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.10 and a Current Ratio set at 7.40.
Earnings analysis for HTG Molecular Diagnostics Inc. [HTGM]
With the latest financial reports released by the company, HTG Molecular Diagnostics Inc. posted -0.15/share EPS, while the average EPS was predicted by analysts to be reported at -0.16/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 6.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for HTGM.
Insider trade positions for HTG Molecular Diagnostics Inc. [HTGM]
There are presently around $7 million, or 36.60% of HTGM stock, in the hands of institutional investors. The top three institutional holders of HTGM stocks are: NANTAHALA CAPITAL MANAGEMENT, LLC with ownership of 5,060,160, which is approximately 0% of the company’s market cap and around 4.10% of the total institutional ownership; COWEN PRIME SERVICES LLC, holding 4,579,500 shares of the stock with an approximate value of $2.08 million in HTGM stocks shares; and PERKINS CAPITAL MANAGEMENT INC, currently with $1.1 million in HTGM stock with ownership of nearly -3.68% of the company’s market capitalization.
17 institutional holders increased their position in HTG Molecular Diagnostics Inc. [NASDAQ:HTGM] by around 1,592,904 shares. Additionally, 17 investors decreased positions by around 3,162,056 shares, while 8 investors held positions by with 11,662,409 shares. The mentioned changes placed institutional holdings at 16,417,369 shares, according to the latest SEC report filing. HTGM stock had 7 new institutional investments in for a total of 1,062,389 shares, while 11 institutional investors sold positions of 2,750,997 shares during the same period.